Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Condition(s):Hepatocellular CancerLast Updated:November 8, 2019Withdrawn
Hide Studies Not Open or Pending
Condition(s):Hepatocellular CancerLast Updated:November 8, 2019Withdrawn
Condition(s):Hepatocellular CancerLast Updated:April 22, 2016Terminated
Condition(s):Hepatocellular CancerLast Updated:September 15, 2017Completed
Condition(s):Liver CancerLast Updated:February 17, 2020Completed
Condition(s):Liver CancerLast Updated:November 21, 2017Terminated
Condition(s):Hepatocellular Cancer; Liver CancerLast Updated:June 10, 2021Completed
Condition(s):Liver NeoplasmsLast Updated:July 4, 2013Withdrawn
Condition(s):Hepatocellular CarcinomaLast Updated:April 25, 2018Completed
Condition(s):Advanced Adult Hepatocellular Carcinoma; Child-Pugh Class A; Stage III Hepatocellular Carcinoma; Stage IIIA Hepatocellular Carcinoma; Stage IIIB Hepatocellular Carcinoma; Stage IIIC Hepatocellular Carcinoma; Stage IV Hepatocellular Carcinoma; Stage IVA Hepatocellular Carcinoma; Stage IVB Hepatocellular CarcinomaLast Updated:December 29, 2023Active, not recruiting
Condition(s):Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver CancerLast Updated:July 9, 2015Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.